Brain

Shanghai Escugen Biotechnology Co., Ltd., a partner of Levena Biopharma, a Sorrento Company, releases positive results from a first-in-human study of ESG401, a TROP2 Antibody Drug Conjugate in patients with locally advanced/metastatic solid tumors at the ASCO 2023 Meeting

Figure 1 Sorrento Therapeutics, Inc. Figure 2 Sorrento Therapeutics, Inc. Figure 3 Sorrento Therapeutics, Inc. CHICAGO, June 05, 2023 (GLOBE...

error: Content is protected !!